PRMT5 and systemic sclerosis: We found the dynamic changes of anti-PRMT5 antibodies in parallel with the progression or regression of skin fibrosis and ILD of SSc; monitoring the levels of anti-PRMT5 antibodies may therefore enable early detection and the initiation of early intervention for the patients with SSc with a higher risk of mRSS progression and development to PF-ILD during follow-up.